EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Epacadostat Overcomes Cetuximab Resistance in Colorectal Cancer by Targeting IDO ‐Mediated Tryptophan Metabolism

Yimin Zhou iD, Qiongyan Tao, Chubin Luo, Jinsong Chen, Genwen Chen, Jianyong Sun

Cancer Science · 2025-06 · 116 (6) · 1715-1729

DOI: 10.1111/cas.70057 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 18.03.2025. Verfasst von Yimin Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Tryptophan, Cetuximab, Indoleamine-Pyrrole 2,3,-Dioxygenase. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Sailing Program, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary or acquired mutations in RAS/RAF genes resulting in cetuximab resistance have limited its clinical application in colorectal cancer (CRC) patients. The mechanism of this resistance remains unclear. RNA sequencing from cetuximab‐sensitive and ‐resistant specimens revealed an activation of the tryptophan pathway and elevation of IDO1 and IDO2 in cetuximab‐resistant CRC patients. In vitro, in vivo, and clinical specimens confirmed the upregulation of IDO1and IDO2 and the Kyn/Trp after cetuximab treatment. Additionally, the IDO inhibitor, epacadostat, could effectively inhibit the migration and proliferation of cetuximab‐resistant CRC cells while promoting apoptosis. Compared to epacadostat monotherapy, the combination of cetuximab and epacadostat showed a stronger synergistic anti‐tumor effect. Furthermore, in vivo experiments confirmed that combination therapy effectively suppressed tumor growth. Mechanistically, KEGG pathway analysis revealed the activation of the IFN‐γ pathway in cetuximab‐resistant CRC tissues. Luciferase reporter assays confirmed the transcriptional activity of IDO1 following cetuximab treatment. Silencing IFN‐γ then suppressed the upregulation induced by cetuximab. Moreover, we observed that the combination reduced the concentration of the tryptophan metabolite kynurenine, promoted the infiltration of CD8 + T lymphocytes, and enhanced the polarization of M1 macrophages within the tumor microenvironment, thereby exerting potent anti‐tumor immune effects. Overall, our results confirm the remarkable therapeutic efficacy of combining cetuximab with epacadostat in cetuximab‐resistant CRC. Our findings may provide a novel target for overcoming cetuximab resistance in CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsTryptophanCetuximabIndoleamine-Pyrrole 2,3,-DioxygenaseDrug Resistance, NeoplasmHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysCell ProliferationApoptosisInterferon-gammaFemaleMice, Inbred BALB CMice, NudeAntineoplastic Combined Chemotherapy ProtocolsCell MovementKynurenineDrug SynergismMaleOximesSulfonamides

Stichwörter der Autor:innen

IDOcetuximabcolorectal cancerepacadostattryptophan metabolismtumor microenvironment

Substanzen

TryptophanCetuximabIndoleamine-Pyrrole 2,3,-DioxygenaseepacadostatIDO1 protein, humanInterferon-gammaKynurenineOximesSulfonamides

Autor:innen und Institutionen

  • Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai, China.
  • Department of Clinical Medicine, Shaoguan University, Shaoguan, Guangdong, China.
  • Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.

ORCID-Profile: Yimin Zhou

Förderung

  • National Natural Science Foundation of China
  • Shanghai Sailing Program
  • China Postdoctoral Science Foundation
  • Outstanding Resident Clinical Postdoctoral Program of Zhongshan Hospital Affiliated to Fudan University

Zitieren

APA

Zhou, Y., Tao, Q., Luo, C., Chen, J., Chen, G., & Sun, J. (2025). Epacadostat Overcomes Cetuximab Resistance in Colorectal Cancer by Targeting IDO ‐Mediated Tryptophan Metabolism. Cancer Science, 116(6), 1715-1729. https://doi.org/10.1111/cas.70057

Vancouver

Zhou Y, Tao Q, Luo C, Chen J, Chen G, Sun J. Epacadostat Overcomes Cetuximab Resistance in Colorectal Cancer by Targeting IDO ‐Mediated Tryptophan Metabolism. Cancer Science. 2025;116(6):1715-1729. doi:10.1111/cas.70057

BibTeX
@article{Zhou2025,
  author = {Zhou, Yimin and Tao, Qiongyan and Luo, Chubin and Chen, Jinsong and Chen, Genwen and Sun, Jianyong},
  title = {Epacadostat Overcomes Cetuximab Resistance in Colorectal Cancer by Targeting IDO ‐Mediated Tryptophan Metabolism},
  journal = {Cancer Science},
  year = {2025},
  volume = {116},
  number = {6},
  pages = {1715--1729},
  doi = {10.1111/cas.70057}
}
Kostenlos starten →